This Healthcare Fund Rode High On Enanta Pharmaceuticals In Q1 – ValueWalk Premium

This Healthcare Fund Rode High On Enanta Pharmaceuticals In Q1

Krensavage Partners gained 8.45% during the first quarter, driven by long positions in Enanta Pharmaceuticals, RTI Surgical Holdings and Invacare Corp. Two biotech shorts negatively impacted the fund's returns. Krensavage outperformed its benchmark S&P Healthcare Index Return's 6.6% gain but came up short of the S&P 500's 13.6% gain.

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles

0